SCHEMBL4334565

SCHEMBL4334565

COc1c(C(=O)NCCSC)ccc2[nH]nc(-c3cc4ccccc4o3)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
MAPT P10636 6/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
KDM4E B2RXH2 5/20 0.40
HSD17B10 Q99714 4/20 0.40
ALDH1A1 P00352 3/20 0.40
HTT P42858 2/20 0.40
MAPK1 P28482 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
JAK2 O60674 1/20 0.39
JAK3 P52333 1/20 0.39
DRD2 P14416 1/20 0.39
DRD3 P35462 1/20 0.39
MKNK1 Q9BUB5 1/20 0.38
NPSR1 Q6W5P4 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4336829 0.87 KDM4E (0.43) MAPTMEN1KMT2AKDM4EHSD17B10
SCHEMBL2866722 0.85 GSK3B (0.41) JAK2JAK3DRD2
SCHEMBL4341547 0.85 BRD4 (0.46) MAPTMEN1KMT2AKDM4EHSD17B10
SCHEMBL4341426 0.84 GAA (0.50) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL2862928 0.83 PIP5K1C (0.46) MAPTMEN1KMT2AKDM4EHSD17B10
SCHEMBL4348178 0.83 LMNA (0.45) LMNAMAPTMEN1KMT2AMAPK1
SCHEMBL4331838 0.83 HPGD (0.53) MEN1KMT2AKDM4EHSD17B10ALDH1A1
SCHEMBL4343252 0.83 HSD17B10 (0.49) MAPTMEN1KMT2AKDM4EHSD17B10
SCHEMBL4327612 0.83 JAK2 (0.40) MAPTMEN1KMT2AKDM4EHSD17B10
SCHEMBL4331216 0.83 JAK2 (0.39) MAPTMEN1KMT2AKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 LMNA 1893/4885MAPT 2644/4885MEN1 3782/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 LMNA 1893/4885MAPT 2644/4885MEN1 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.